Heterocyclic sulfonamide derivativesThe present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds have been demonstrated as inhibitors of MEK and therefore may be useful in the treatment of hyperproliferative diseases (e.g., cancer and inflammation).The compound of formula (i) or its pharmaceutically useful salt:whereinx is n or c (h);r 1be randomly by one or more substituted aryl of substituting group or heteroaryls that are selected from tabulation 1 independently of one another; r 2be h or (c 1-c 6) alkyl; r 3be h, (c 1-c 6) alkyl, halo (c 1-c 6) alkyl or hydroxyl-substituted (c 1-c 6) alkyl; r 4be h, halogen, (c 1-c 6) alkyl or halo (c 1-c 6) alkyl; r 5be h, halogen, (c 1-c 6) alkyl or halo (c 1-c 6) alkyl; r 6be h or (c 1-c 6) alkyl; r 7be a kind of (c that is selected from 1-c 6) alkyl, (c 2-c 6) alkenyl, (c 2-c 6) alkynyl, (c 1-c 6) alkylamino, two-((c 1-c 6) alkyl) chemical part of amino, naphthenic base, aryl, heterocyclylalkyl and heteroaryl, wherein said chemical part randomly is selected from halogen, cyanic acid, (c by one to three independently of one another 2-c 6) alkenyl, hydroxyl, (c 1-c 6) alkoxyl group, (c 2-c 6) alkenyloxy, (c 2-c 6) alkynyloxy group, (c 1-c 6) alkylthio, halo (c 1-c 6) alkyl, amino, (c 1-c 6) alkylamino, two-((c 1-c 6) alkyl) amino, (c 1-c 6) acyl amino, (c 1-c 6) acyl group (c 1-c 6) alkylamino, (c 3-c 7) substituting group of naphthenic base or 3-to 7-element heterocycle alkyl replaces, wherein said naphthenic base and said heterocyclylalkyl randomly are selected from halogen, cyanic acid, hydroxyl, (c by one or two independently of one another 2-c 6) alkenyl, (c 1-c 6) alkoxyl group, (c 2-c 6) alkenyloxy, (c 2-c 6) alkynyloxy group, benzyloxy (c 1-c 4) alkyl, (c 1-c 6) alkylthio, halo (c 1-c 6) alkyl, amino, (c 1-c 6) alkylamino, two-((c 1-c 6) alkyl) amino, (c 1-c 6) acyl amino or (c 1-c 6) acyl group (c 1-c 6) substituting group of alkylamino replaces; tabulation 1 is selected from hydroxyl, cyanic acid, nitro, (c 1-c 6) alkyl, (c 2-c 6) alkenyl, (c 2-c 6) alkynyl, (c 1-c 6) alkoxyl group, (c 2-c 6) alkenyloxy, (c 2-c 6) alkynyloxy group, halogen, (c 1-c 6) alkyl-carbonyl, carboxyl, (c 1-c 6) alkoxy carbonyl, amino, (c 1-c 6) alkylamino, two-((c 1-c 6)) alkylamino, (c 1-c 6) alkyl amino-carbonyl, two-((c 1-c 6) alkyl) aminocarboxyl, (c 1-c 6) alkyl-carbonyl-amino, (c 1-c 6) alkyl-carbonyl ((c 1-c 6) alkyl) amino, (c 1-c 6) alkyl sulfonyl-amino, (c 1-c 6) alkyl sulphonyl ((c 1-c 6) alkyl) amino, (c 1-c 6) alkyl-s-, (c 1-c 6) alkyl s (o)-, (c 1-c 6) alkyl-so 2-, nh 2-so 2-, (c 1-c 6) alkyl n (h)-so 2-and two-((c 1-c 6) alkyl) n-so 2-, wherein above-mentioned hydrocarbon key is separately randomly by one or more halogen, hydroxyl, (c of being selected from independently of one another 1-c 6) alkoxyl group, amino, (c 1-c 6) alkylamino, two-((c 1-c 6) alkyl) substituting group of amino or cyanic acid replaces.
헤테로시클릭 술폰아미드 유도체본 발명은 하기 화학식 I의 화합물 및 그의 제약상 허용되는 염에 관한 것이다. <화학식 I> 상기 화합물은 MEK의 억제제로서 입증되었고, 따라서 이는 과다증식성 질환 (예를 들어, 암 및 염증)의 치료에 유용할 수 있다.하기 화학식 I의 화합물 또는 그의 제약상 허용되는 염.<화학식 I>[이미지]상기 식에서,X는 N 또는 C(H)이고;R1은, 목록 1로부터 각각 독립적으로 선택된 1개 이상의 치환기로 임의로 치환된 아릴 또는 헤테로아릴이고;R2는 H 또는 (C1-C6)알킬이고;R3은 H, (C1-C6)알킬, 할로-치환된 (C1-C6)알킬 또는 히드록시-치환된 (C1-C6)알킬이고;R4는 H, 할로겐, (C1-C6)알킬 또는 할로-치환된 (C1-C6)알킬이고;R5는 H, 할로겐, (C1-C6)알킬 또는 할로-치환된 (C1-C6)알킬이고;R6은 H 또는 (C1-C6)알킬이고;R7은, (C1-C6)알킬, (C2-C6)알케닐, (C2-C6)알키닐, (C1-C6)알킬아미노, 디-((C1-C6)알킬)아미노, 시클로알킬, 아릴, 헤테로시클로알킬 및 헤테로아릴로 이루어진 군으로부터 선택되는 화학적 잔기이며, 상기 화학적 잔기는, 할로겐, 시아노, (C2-C6)알케닐, 히드록실, (C1-C6)알콕시, (C2-C6)알케닐옥시, (C2-C6)알키닐옥시, (C1-C6)알킬티오, 할로-치환된(C1-C6)알킬, 아미노, (C1-C6)알킬아미노, 디-((C1-C6)알킬)아미노, (C1-C6)아실아미노, (C1-C6)아실(C1-C6)알킬아미노, (C3-C7)시클로알킬 또는 3 내지 7원 헤테로시클로알킬 (여기서, 상기 시클로알킬 및 상기 헤테로시클로알킬은, 할로겐, 시아노, 히드록실, (C2-C6)알케닐, (C1-C6)알콕시, (C2-C6)알케닐옥시, (C2-C6)알키닐옥시, 벤질옥시(C1-C4)알킬, (C1-C6)알킬티오, 할로-치환된(C1-C6)알킬, 아미노, (C1-C6)알킬아미노, 디-((C1-C6)알킬)아미노, (C1-C6)아실아미노 또는 (C1-C6)아실(C1-C6)알킬아미노로부터 각각 독립적으로 선택된 1 또는 2개의 치환기로 임의로 치환됨)로부터 각각 독립적으로 선택된 1 내지 3개의 치환기로 임의로 치환되고;목록 1은 히드록실, 시아노, 니트로, (C1-C6)알킬, (C2-C6)알케닐, (C2-C6)알키닐, (C1-C6)알콕시, (C2-C6)알케닐옥시, (C2-C6)알키닐옥시, 할로겐, (C1-C6)알킬카르보닐, 카르복시, (C1-C6)알콕시카르보닐, 아미노, (C1-C6)알킬아미노, 디-((C1-C6))알킬아미노, (C1-C6)알킬아미노카르보닐, 디-((C1-C6)알킬)아미노카르보닐, (C1-C6)알킬카르보닐아미노, (C1-C6)알킬카르보닐((C1-C6)알킬)아미노, (C1-C6)알킬술포닐아미노, (C1-C6)알킬술포닐((C1-C6)알킬)아미노, (C1-C6)알킬-S-, (C1-C6)알킬S(O)-, (C1-C6)알킬-SO2-, NH2-SO2-, (C1-C6)알킬N(H)-SO2- 및 디-((C1-C6)알킬)N-SO2-로부터 선택되며, 상기 언급한 각각의 탄화수소 결합은 할로겐, 히드록실, (C1-C6)알콕시, 아미노, (C1-C6)알킬아미노, 디-((C1-C6)알킬)아미노 또는 시아노로부터 각각 독립적으로 선택된 1개 이상의 치환기로 임의로 치환된다.